Brief: Ovid Therapeutics Doses Healthy Volunteers With OV329 In Phase 1 Trial
05/01/2023 14:19
Jan 5 (Reuters) - Ovid Therapeutics Inc OVID.O :
* OVID THERAPEUTICS DOSED HEALTHY VOLUNTEERS WITH OV329 IN
PHASE 1
TRIAL
* OVID THERAPEUTICS INC - EXPECTS TO ENROLL MORE THAN 60
INDIVIDUALS IN THIS TRIAL AND ANTICIPATES FINAL RESULTS IN FIRST
HALF OF 2024
Source text for Eikon: ID:nGNX4fqtQR
Further company coverage: OVID.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ovid Therapeutics
See all newsOvid Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Ovid Therapeutics Q2 revenue beats estimates
Brief: Ovid Therapeutics Q2 EPS USD -0.08
Ovid Therapeutics Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Ovid Therapeutics Appoints Leading Physician-Scientist And Biotech Innovator Anna Greka, M.D., Ph.D., To Board Of Directors